key: cord-0925470-ek81d43v authors: do Monte Junior, Epifanio Silvino; dos Santos, Marcos Eduardo Lera; Ribeiro, Igor Braga; Luz, Gustavo de Oliveira; Baba, Elisa Ryoka; Hirsch, Bruno Salomão; Funari, Mateus Pereira; de Moura, Eduardo Guimarães Hourneaux title: Rare and Fatal Gastrointestinal Mucormycosis (Zygomycosis) in a COVID-19 Patient: A Case Report date: 2020-11-19 journal: Clin Endosc DOI: 10.5946/ce.2020.180 sha: 8fd168084dd3b968d2a8598caede1085fa2cc835 doc_id: 925470 cord_uid: ek81d43v The novel coronavirus disease (COVID-19) quickly spread to all continents. However, data regarding all the signs and symptoms of COVID-19 are insufficient. Patients with COVID-19 might present higher susceptibility to fungal coinfections. Mucormycosis is a rare and often life-threatening fungal disease characterized by vascular invasion by hyphae, resulting in thrombosis and necrosis. This is the first case report of mucormycosis in a COVID-19 patient. An 86-year-old male patient was admitted to the emergency room with acute diarrhea, cough, dyspnea, and fever from 5 days prior. Blood tests revealed a hemoglobin level of 14.3 mg/dL. Five days following the admission, the patient presented with melena and a hemoglobin level of 5.6 mg/dL. A transfusion of three units of red blood cells was required. Esophagogastroduodenoscopy revealed two giant gastric ulcers with necrotic debris and a deep hemorrhagic base without active bleeding. Furthermore, biopsies confirmed mucormycosis. Despite intensive care, the patient died 36 hours after the esophagogastroduodenoscopy. mg/dL, a leukocyte count of 11.2 × 109/L, lymphocyte count of 0.58 × 10 9 /L, a D-dimer level of 602 ng/mL, a lactate dehydrogenase level of 850 U/L, a creatinine level of 2.34 mg/dL, and a urea level of 93 mg/dL. A throat swab was collected from the patient, which confirmed COVID- 19 . Computed tomography of the chest was performed, and the findings are demonstrated in Fig. 1 . Due to acute respiratory failure and hemodynamic instability, he was transferred to the intensive care unit (ICU). The patient was initially treated with ceftriaxone, azithromycin, oseltamivir, and hydrocortisone, besides intensive care management including vasopressors and mechanical ventilation. Five days following ICU admission, the patient presented with melena and severe anemia (hemoglobin level of 5.6 mg/ dL). Physical examination revealed mild abdominal tenderness. He was managed with three units of red blood cells and omeprazole. Esophagogastroduodenoscopy (EGD) revealed two giant gastric ulcers with dirty debris and a deep hemorrhagic base without active bleeding located in the greater and lesser curvature (Fig. 2 ). Pathological examination confirmed mucormycosis (Fig. 3) . Unfortunately, the patient died 1 week following hospitalization, 36 hours after the EGD, and before a diagnosis was established. Antifungal agents were not administered. The ongoing outbreak of COVID-19 originated in Wuhan, China, in December 2019. COVID-19, which is the disease associated with SARS-CoV-2 infection, spread rapidly to produce a global pandemic. 10 The spectrum of symptomatic SARS-CoV-2 infection ranges from mild to critical. The proportion of severe or fatal infections may also vary by location. Patients with COVID-19 might present with markedly higher levels of inflammatory cytokines (such as interleukin [IL]-2R, IL-6, IL-10, and tumor necrosis factor-alpha), associated with impaired cell-mediated immune response, affecting both CD4 + T and CD8 + T cells. Hence, an increased susceptibility to fungal coinfections is observed. 11 Mucormycosis is characterized by infarction and necrosis of the host tissues that result from an invasion of the vasculature by hyphae. Depending on the anatomic site involved, mucormycosis can present as a variety of different syndromes, including rhino-orbital-cerebral, pulmonary, cutaneous, and less often GI, renal, and disseminated diseases. 12 GI involvement presents in approximately 8% of the cases. The most commonly affected organs in the GI tract include the stomach and colon. The symptoms of GI mucormycosis may include fever, nausea, abdominal pain, GI bleeding, and perforation. Establish- ing a correct diagnosis is challenging due to the nonspecific clinical signs/symptoms, which may not result in suspicions of mucormycosis. The endoscopic appearance of gastric mucormycosis is usually a large ulcer with necrosis, eventually presenting an adherent, thick, green exudate. 13, 14 Diagnosis is confirmed by histopathologic identification based on the biopsy of the suspected area during surgery or endoscopy. 6 The disease has a high fatality rate (up to 85%) related to late or no diagnosis. 15 Treatment involves surgical debridement of involved tissues and antifungal therapy. Intravenous amphotericin B (a lipid formulation) is the drug of choice for initial therapy. 16 Despite early diagnosis and aggressive combined surgical and medical therapy, the prognosis for recovery from mucormycosis is poor. 6 We presented a case of an elderly patient whose only known comorbidity was arterial hypertension, without traditional risk factors for developing mucormycosis. He was admitted following the diagnosis of COVID-19 and acute respiratory failure and managed with broad-spectrum antibiotics and corticosteroids (which are risk factors for invasive fungal disease). 17 It is known that COVID-19 may be associated with immune dysregulation, 18 and it has been reported that patients with COVID-19 might be at risk of developing invasive fungal infections, such as invasive aspergillosis, candidiasis, and Pneumocystis jiroveci infection. 11, 19 However, there are no reports of mucormycosis associated with COVID-19. Our patient was diagnosed with primary gastric mucormycosis, but it is unknown whether the cause of death was invasive mucormycosis. GI mucormycosis is a rare disease, and it should be considered if an atypical gastric ulcer is identified in a COVID-19 patient. Clinical suspicion and prompt treatment are fundamental to achieve the cure of the disease. Hence, preemptive therapy should be considered in the presence of features suggesting mucormycosis. More studies are necessary to determine if these two pathologies are related. Case report: gastric mucormycosis-a rare but important differential diagnosis of upper gastrointestinal bleeding in an area of Helicobacter pylori endemicity Zygomycosis: an emerging fungal infection with new options for management The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the mycoses study group education and research consortium Epidemiology and outcome of zygomycosis: a review of 929 reported cases Clinical characteristics of coronavirus disease 2019 in China The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak Diagnostic characteristics of serological-based COVID-19 testing: a systematic review and meta-analysis CRISPR-Cas12-based detection of SARS-CoV-2 Fungal co-infections associated with global COVID-19 pandemic: a clinical and diagnostic perspective from China Breaking the mold: a review of mucormycosis and current pharmacological treatment options Fatal invasive gastric mucormycosis occurring with emphysematous gastritis: case report and literature review Gastrointestinal manifestations and associated health outcomes of COVID-19: a Brazilian experience from the largest South American public hospital Epidemiology and clinical manifestations of mucormycosis Recent advances in the management of mucormycosis: from bench to bedside Opportunistic fungal infections in the epidemic area of COVID-19: a clinical and diagnostic perspective from Iran Clinical and immunological features of severe and moderate coronavirus disease 2019 COVID-19 associated pulmonary aspergillosis ORCID Epifanio Silvino do Monte Junior: https://orcid.org/0000-0001-7304-8222 Marcos Eduardo Lera dos Santos: https://orcid.org/0000-0001-9759-3807 Gustavo de Oliveira Luz: https://orcid.org/0000-0001-7396-8440 Elisa Ryoka Baba: https://orcid.org/0000-0001-7261-9054 Bruno Salomão Hirsch: https://orcid.org/0000-0002-0777-0150 Mateus Pereira Funari: https://orcid.org/0000-0002-4828-9320 Eduardo Guimarães Hourneaux de Moura: https://orcid.org/0000-0002-8023-3722